Poultry industry plays an important role in sustaining economy of India. Despite routine vaccination strategies has been a common practice to control commonly occurring diseases in poultry, outbreaks are commonplace. Recently, emergence of genotype XIII strains of NDV resulted in widespread economic losses in India. We prepared inactivated oil adjuvant vaccine derived from Lasota, ndv53/Haryana or ndv52/Sarsa, which is recently isolated genotype XIII virus in India. Three groups of SPF chickens were vaccinated once with each vaccine and serum samples were collected every 7 days interval and tested for HI titres with three different antigens prepared from same virus to assess cross neutralization antibodies amongst them. All three vaccines have shown some degree of cross reactivity after 14 days post vaccination. However, vaccine prepared from Lasota, a genotype II virus failed to generate significant titers against both ndv53/Haryana and ndv52/Sarsa. Our observation explains recent outbreaks of genotype XIII viruses in the field and necessitates development of new vaccines to control the recently emerged NDV strains in India.
Newcastle disease (ND), a contagious disease caused by the Newcastle disease virus (NDV), is persistent throughout the world.NDV belongs to the genus Avulavirus in the subfamily Paramyxovirinae, family Paramyxoviridae and order Mononegavirales, which affects many species of birds. ND is caused by an APMV1 virus of the Avulavirusgenus which includes ten other serotypes (APMV 2-11) 1 . Since 1926, four epizootics has occurred throughout the world, each involving NDV viruses from different genotypes [2] [3] [4] [5] .NDV is persistent in India since its isolation in 1928 and has been reported from the chickens as well as wild and pet birds from different parts of India. Newcastle disease is considered enzootic in India due to increased commercialization of poultry industry and augmented use of poultry products. Clinical manifestation of the disease depends upon various factors main being the type of the isolate involved in the disease. The disease varies in severity and based on the severity of disease the strains are divided in to three different categories viz. lentogenic, mesogenic and velogenic. Level of pathogenicity is mainly attributed to the amino acid (aa) sequence at the Fusion Protein Cleavage Site (FPCS) which is 112 R/K-R-Q-R/K-R"!F 117 in case of very virulent, velogenic and mesogenic strains 6 . Poultry industry plays an important role in sustaining economy of India. It is imperative that continuous surveillance of prevalent NDVs will help to survey of NDVs circulating in the environment and ultimately leads to effective control of ND in India. As a prophylactic measure against NDV, chickens are routinelyvaccinated with NDV vaccines derived from known strains such as LaSota and other genotype II vaccine strains. Recently, we reported outbreaks of NDV in the vaccinated flocks of Gujarat, Haryana, West Bengal, Andhra Pradesh and Tamil Nadu. We also reported detailed phylogenetic and sequence analysis of NDVs isolated from the outbreaks 7 . Some of theseisolates, including the Gujarat isolate ndv52/Sara, wereobtained from chickens that had been vaccinated severaltimes with current NDV vaccines. The results from the study revealed that genotype XIII NDVs are of distinct antigenicity then commonly used and available vaccine strains. In other words it can be said that currently available vaccines will not protect against field infection of genotype XIII NDVs. All strains of Newcastle disease virus will agglutinate chicken red blood in vitro. The process is known as haemagglutination and is the basis of the common serological test, the haemagglutination-inhibition test, used to detect antibodies to this virus.The aim of present study was to compare efficacy of Newcastle disease's killed vaccines (Lasota, ndv53/Haryana and ndv52/ Sarsa) in broilers using HI method to assess the cross naturalization antibodies amongst them and to predict cross protection against challenge.
Materials and Methods
Three-week old SPF chickens were used in the study. Before thechickens were used in the experiment, they were tested for themajor viral diseases that affect chickens, including NDV, Infectious bursal disease, and Infectious bronchitis. The SPF birds were reared in a isolator till 3 weeks of age then vaccinated, color identified and reared in the cages with adequate food and water for throughout the experimental period and serum was collected in the regular interval for serological studies.
The three viruses Lasota, ndv52/Sasra and ndv53/Haryana were used for preparing inactivated oil adjuvant vaccine and antigen preparation. The genotype XIII strain ndv52/Sarsa and the genotype II strain ndv53/Haryana were recently isolated from vaccinated flock of Sasra poultry farm of Gujarat and poultry farm of Haryana, respectively. The viruses were propagated in 11 days SPF embryos followed by the quantification of the viruses through EID 50. Viruses were inactivated by using 0.5% formalin. Oil adjuvant vaccine was prepared keeping 30:70 ratio of antigen and oil adjuvantThe virus titer was adjusted in such a way that all the trial vaccine formulation were contenting 1x 10 8 EID50 per dose. All the viruses were stored in LN2 until use. The viral antigen was generated by purification of the virus from allantoic fluid of the dead embryos inoculated with 10 -5 dilution followed by further propagation in large quantity ofallantoic fluid in 11 days old embyonated SPF eggs. The viral antigen was tested for extraneous pathogens and sterility for bacterial & fungal contaminants to test the purity and found to be pure.
Forty SPF chickens were divided in to 4 different groups of each having 10 birds. Three locally produced inactivated oil adjuvant vaccines prepared from Lasota, ndv52/Sarsa and ndv53/ Haryana were used in the study. Three groups each of 10 SPF birds of 3 weeks of age were vaccinated with 0.5ml of inactivated vaccine subcutaneously in the middle of the neck and reared for 4 weeks. The forth group of 10 SPF birds was not vaccinated and reared separately which acted as control. The serum samples were collected every 7 days interval and tested for HI titres with three different antigen to observe the cross naturalization antibodies amongst them to predict cross protection against challenge.
HI test was done according to the procedure of OIE 
A three-way ANOVA and paired t-test were performed toevaluate the influence of multiple variables on theserological data. The vaccine strain (Lasota, ndv52/Sarsa and ndv53/Haryana),the antigen (Lasota, ndv52/Sarsa and ndv53/Haryana), and the test time (7 day pv or 21 day pv) served as independentvariables. Variation among these three variables wasanalyzed by using a three-way ANOVA. Variation in theantibody titers at 7 day pv and 21 day pv within each factorcategory was analyzed by using paired t-test. Variationbetween or within groups was considered to be significantat p "ÿ 0.05.
results
Sera were taken from chickens on every 7 dayinterval and the anti-NDV antibody titers were determined bythe HI testwith three different antigen to observe the cross naturalization antibodies amongst them to predict cross protection against challenge. None of the control birds had detectableHI antibodies to NDV during the course of the study. Theserologic results were analyzed by using a three-way multiple ANOVA based on three independent variables (Table 1) . At 7 days post vaccination, the Lasota vaccine grouphad a significantly higher geometric mean HI antibody titer against Lasota antigen as compared to that of the other vaccine groups (p "ÿ 0.05).On day 21 after vaccinationall vaccine groups showed significant increases in HI antibody titers(paired t-test, p "ÿ 0.05) except Lasota vaccinated group against Sarsa antigen. These rises in HI titers between 7 and 21 day pv were not observed in either control vaccine group. Haryana vaccine group revealed significantly higher geometric mean HItitersagainst Haryana antigen on day 21 pvfollowed by Sarsa and Lasota vaccine groups. Similarly, Sarsa vaccine group revealed significantly higher geometric mean HItitersagainst Sarsa antigen on day 21 pvfollowed by Haryana and Lasota vaccine groups. Lasota vaccine group revealed significantly higher geometric mean HItitersagainst Lasota antigen on day 21 pvfollowed by Sarsa and Haryana vaccine groups.
discussion
Newcastle disease is an important disease of commercial and backyard poultry farming system considering economic and production losses rendered by the virus. Currently, vaccines made from genotype II ND viruses are most commonly used vaccines as prophylactics against ND in India. Despite extensive use of prophylactic vaccination, outbreaks of ND are still recorded due to continuous evolvement of the virus circulating in the field. Additionally, several studies has pointed p,q,r Values with different superscripts within column differ significantly (p < 0.05). dpv: day post vaccination out that classic inactivated or live vaccines made from genotype I or II NDV strains can prevent the clinical disease and increase survival but do not prevent virus replication and shedding 9-11 . Failure to control NDV with available vaccines necessitates continuous surveillance and the need to access protection offered by currently available vaccines and to develop new vaccines to prevent the spread. Earlier, we reported outbreak of genotype XIII NDV from India employing whole genome sequence analysis. This observation suggested that the antigenic variant genotype XIII may be responsible for the continuingoutbreaks of ND in India.Here, we attempted to assess whether a vaccine made from genotype II or XIII isolate can generatecross protective antibodies against genotype XIII or II viruses. We observed significantly high HI titres in case of homologous genotype matching vaccines, while cross protecting antibodies were less as compared to genotype matching vaccines. Our observation suggests that the differences in whole genome sequence and especially at the level of the F and HN glycoproteinsbetween challenge and vaccine viruses may be responsible for failure of vaccine to prevent transmission of disease.We found that these vaccines provide chickens with safe protection,as no mortality or disease symptoms were observed in anyof the vaccinated chickens. The vaccines made from genotype II viruses were successful in generating cross protective antibodies against genotype XIII viral antigen. The vaccines made from genotype II viruses were significantly less protective as compared to Sarsa strain, which is a recently prevalent NDV genotype XIII strain. Most widely used NDV vaccine strains in India, LaSota and B1 (genotype II),are genetically distant from the genotypes of NDV currentlycausing outbreaks in several regions of the world (II, IV, VII, XIII, etc.) 12 . The results reported by us are in accordance with earlier studies, which demonstrated thatchickens vaccinated with the LaSota strain were fullyprotected from challenge with heterologous NDV strainsof different genotypes 13, 14 . It is very well studied and demonstrated that genotype matched vaccines effectively reduced virus shedding and provided better protection [15] [16] [17] . In conclusion, our results revalidate advantages conferred by the use of genotype matching vaccines homologous to circulating NDV in producing increased level of specific antibodies. The study also emphasizes the need of developing high quality genotype matching vaccine for recently emerged virulent strains of genotype XIII in India. It is imperative that to protect chickens fromNDV and prevent the virus spread, it isimportant to maintain solid and potent immunogenicity preferably by genotype matching vaccines.TheDIVA (differentiation between vaccinated and infectedanimals) vaccines based on subunit, recombinant, and DNA vaccines [18] [19] [20] [21] [22] , might be more successful in preventing viral spread of NDV in endemic country such as India. The furtherextension of this experiment would beto repeat this experiment with virulent virus challenge in commercial birds and to determine cross protective efficiency of genotype specific vaccines.
